Equities

Sonovia Ltd

SONO:TLV

Sonovia Ltd

Actions
Basic MaterialsChemicals
  • Price (ILa)67.50
  • Today's Change-3.50 / -4.93%
  • Shares traded195.31k
  • 1 Year change-75.09%
  • Beta1.9222
Data delayed at least 20 minutes, as of May 22 2024 12:57 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Nano Textile Ltd, formerly TAB Anti-Bacterial Textiles Ltd, is an Israel-based development stage company focused on the development and production of anti-bacterial textile products. The Company obtained an exclusive license to exploit the Patent Rights in Europe, Asia, South America, and Australia for the production and marketing of non-disposable bed linen, drapery, upholstery, home textile and/or clothing, through its license agreement with Bar Ilan Research and Development Ltd (BIRAD). Its planned segments are: anti-bacterial fabric rolls for sale to textile manufacturers who will produce and sell the final anti-bacterial products to end-user customers; private label anti-bacterial textile products for sale directly to hospitals and various medical institutions, and anti-bacterial textile products for the private/consumer market.

  • Revenue in ILS (TTM)0.00
  • Net income in ILS-26.68m
  • Incorporated2013
  • Employees44.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Erech Finance Cahalacha Ltd282.00k-25.29m8.16m18.00--1.88--28.94-9.97-9.970.11121.710.0061--0.019---53.84-15.68-132.10-31.24-659.2266.49-8,841.49-133.65---11.040.7966---97.35-50.83-1.01------
Nextgen Biomed Ltd0.00-9.00m8.23m187.00--0.7161-----2.70-2.700.001.420.00-------51.61-32.00-54.98-35.24------------0.1054-------236.16------
Human Xtensions Ltd4.95m-36.64m10.76m50.00--0.412--2.17-1.37-1.370.1850.97570.09220.46342.2199,000.00-68.25-49.34-77.27-55.6951.6649.34-740.10-485.434.75--0.0608--56.00--17.84---19.95--
Sonovia Ltd0.00-26.68m11.63m44.00--0.3605-----1.65-1.480.001.960.00----0.00-55.93---62.66-------------13.620.0054-------187.75--77.26--
Elbit Medical Technologies Ltd1.28m-65.20m18.05m232.00--0.6826--14.16-0.7264-0.72640.01460.29150.0211--38.67---108.0237.04-110.4338.19-----5,113.2241.14---0.0110.00--314.29-55.19-248.15------
BioLight Life Sciences Ltd118.00k-26.02m19.30m4.00--0.6481--163.54-5.60-5.600.02556.390.0026--0.290329,500.00-60.77-20.22-65.01-21.13-----23,294.07-12,746.09---0.63260.003--87.30-49.76-231.59--92.16--
Erika B-Cure Laser Ltd29.88m-19.22m31.87m----1.34--1.07-0.185-0.1850.28760.22780.51840.39454.08---33.34---49.63--76.9587.63-64.32-14.480.8936--0.1726---40.62-3.4040.97---19.27--
Allmed Solutions Ltd0.001.42m32.58m19.0018.600.686417.16--0.01820.01820.000.49240.00----0.002.431.432.681.59--50.43--15.58----0.0154------111.71---10.48--
Endymed Ltd83.46m2.03m43.82m46.0021.110.78311.970.5250.15090.15096.134.071.132.4618.631,814,446.002.7510.383.3813.3251.2051.922.438.913.02--0.0771--6.774.30-34.94-22.83-15.24--
Data as of May 22 2024. Currency figures normalised to Sonovia Ltd's reporting currency: Israeli Shekel ILS
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.